None listed
Conditions
Interventions
Medical Device : The patients with 24-hour ambulatory systolic BP 130-159 mmHg and serum LDL-cholesterol <130 mg/dl were classified as [Category 1]. [Category 2] includes the patients with 24-hour amb
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: health insurance subscribers who are aged 20-54 years 24-hour ambulatory systolic BP 130-159 mmHg or serum LDL =130 mg/dl Android smartphone users who can use ICT-based helathcare application no use of anti-hypertensive or lipid-lowering drugs for =3 months prior to screening subjects who are considered appropriate to be managed with lifestyle modification for 12 weeks Subject who understands the purpose of the study and signs with informed consent form
Exclusion criteria
Exclusion criteria: 24-hour ambulatory systolic or diastolic BP >160 mmHg or > 110 mmHg underlying cardiovascular disease (ischemic heart disease, heart failure, aortic disease, valvular heart disease, arrhythmia, cardiomyopathy, etc.) underlying cerebrovascular disease (stroke, cerebral infarction or hemorrhage, cerebral aneurysm, etc.) chronic renal disease peripheral vascular disease pregnancy secondary hypertension atrial fibrillation or flutter severe bradyarrhythmia difficulty in BP measurement by smart watch difference in systolic BP measurements from both arms > 10mmHg life expectancy < 2 years medical conditions that would limit adherence to participation (as confirmed by physicians)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in 24-hour ambulatory systolic BP from baseline to 12 weeks [Time Frame: at 12-week follow-up] in patients with hypertension [Category 1 & 3] Mean change in serum LDL-cholesterol level from baseline to 12 weeks [Time Frame: at 12-week follow-up] in patients with hyperlipidemia [Category 2 & 3] | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean change in 24-hour ambulatory diastolic BP from baseline to 12 weeks [Time Frame: at 12-week follow-up] Mean change in daytime systolic BP from baseline to 12 weeks [Time Frame: at 12-week follow-up] Mean change in daytime diastolic BP from baseline to 12 weeks [Time Frame: at 12-week follow-up] Mean change in nighttime systolic BP from baseline to 12 weeks [Time Frame: at 12-week follow-up] Mean change in nighttime diastolic BP from baseline to 12 weeks [Time Frame: at 12-week follow-up] change in diurnal variability of BP from baseline to 12 weeks [Time Frame: at 12-week follow-up] percent of subjects achieving the target BP [Time Frame: at 12-week follow-up] percent of subjects achieving the target LDL-cholesterol [Time Frame: at 12-week follow-up] change in serum triglyceride from baseline to 12 weeks [Time Frame: at 12-week follow-up] change in serum HDL-cholesterol from baseline to 12 weeks [Time Frame: at 12-week follow-up] change in body mass index from baseline to 12 weeks [Time Frame: at 12-week follow-up] change in quality of life (EuroQOL) from baseline to 12 weeks [Time Frame: at 12-week follow-up] change in activity score (IPAQ) from baseline to 12 weeks [Time Frame: at 12-week follow-up] change in smart watch-measured mean systolic BP from baseline to 12 weeks [Time Frame: at 12-week follow-up] change in smart watch-measured mean diastolic BP from baseline to 12 weeks [Time Frame: at 12-week follow-up] | — |
Countries
Korea, Republic of
Contacts
Public ContactJIEUN LEE
Asan Medical Center
Outcome results
None listed